How Tysabri survived

Nature Biotechnology

Volumn 27, Issue 11, 2009, Pages 986-

  Huggett, Brady ^a  

^a Nature Biotechnology ^*

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; EFALIZUMAB; NATALIZUMAB; ROFECOXIB; TROVAFLOXACIN;

DRUG APPROVAL; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; JC VIRUS; MULTIPLE SCLEROSIS; NOTE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LICENSURE; MULTIPLE SCLEROSIS; RISK MANAGEMENT; SAFETY-BASED DRUG WITHDRAWALS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 70449336507     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1109-986     Document Type: Note

References (2)

1. Polman, C.H. et al. N. Engl. J. Med. 354, 899-910 (2006).
2. Rudick, R.A. et al. N. Engl. J. Med. 354, 911-923 (2006).